The Orgenesis Inc (ORGS) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered ORGS. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for ORGS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Orgenesis Inc has a total of 1 Wall St Analyst ratings. There are 1 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Orgenesis Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ORGS.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Kenneth Bruce Benchmark | Speculative Buy | $6 | Reiterates | Jun 14, 2023 |
Kenneth Bruce Benchmark | Buy | $6 | Reiterates | Mar 22, 2023 |
Benchmark | Speculative Buy | $9 | Initiates | Sep 26, 2019 |
When did it IPO
N/A
Staff Count
146
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Vered Caplan M.Sc.
Market Cap
$34.2M
In 2023, ORGS generated $530,000 in revenue, which was a decrease of -98.53% from the previous year. This can be seen as a signal that ORGS's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.